Amplia Therapeutics Limited
INNMF · OTC
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | 68.9% | -29.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 94.1% | 95% | 83.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -158.1% | -196.1% | -166.8% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | -$0 | $0 | $0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -158.1% | -200% | -168.3% |
| EPS | -0.007 | -0.01 | -0.011 | -0.017 |
| % Growth | 37.5% | 6.3% | 36.2% | – |
| EPS Diluted | -0.007 | -0.01 | -0.011 | -0.017 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | -$0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -167.5% | -199% | -171.7% |